Ulcerative Colitis Concomitant with Cytomegalovirus Infection, Bullous Sweet’s Syndrome, and Acute Myeloid Leukemia: A Case Report and Literature Review

References

• Taku K, Britta S, Chen WS, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6(1):73.
   PubMedGoogle Scholar
• Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785–1794. doi:10.1053/j.gastro.2011.01.055
   PubMed Web of Science ®Google Scholar
• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–e30. doi:10.1053/j.gastro.2011.10.001
   PubMed Web of Science ®Google Scholar
• Mao R, Chen M. Precision medicine in IBD: genes, drugs, bugs and omics. Nat Rev Gastroenterol Hepatol. 2022;19(2):81–82. doi:10.1038/s41575-021-00555-w
   PubMed Web of Science ®Google Scholar
• Chang JT, Longo DL. Pathophysiology of inflammatory bowel diseases. N Engl J Med. 2020;383(27):2652–2664. doi:10.1056/NEJMra2002697
   PubMed Web of Science ®Google Scholar
• Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology. 2021;161(4):1118–1132. doi:10.1053/j.gastro.2021.07.042
   PubMed Web of Science ®Google Scholar
• Argollo M, Gilardi D, Peyrin-Biroulet C, et al. Comorbidities in inflammatory bowel disease: a call for action. Lancet Gastroenterol Hepatol. 2019;4(8):643–654. doi:10.1016/S2468-1253(19)30173-6
   PubMed Web of Science ®Google Scholar
• Dave M, Purohit T, Razonable R, et al. Opportunistic infections due to inflammatory bowel disease therapy. Inflamm Bowel Dis. 2014;20(1):196–212. doi:10.1097/MIB.0b013e3182a827d2
   PubMed Web of Science ®Google Scholar
• Rahier JF, Magro F, Abreu C, et al. European Crohn’s and Colitis Organisation (ECCO) second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8(6):443–468. doi:10.1016/j.crohns.2013.12.013
   PubMed Web of Science ®Google Scholar
• Dave M, Papadakis KA, Faubion WA Jr. Immunology of inflammatory bowel disease and molecular targets for biologics. Gastroenterol Clin North Am. 2014;43(3):405–424. doi:10.1016/j.gtc.2014.05.003
   PubMed Web of Science ®Google Scholar
• Chapman TP, Gomes CF, Louis E, Colombel JF, Satsangi J. De-escalation of immunomodulator and biological therapy in inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2020;5(1):63–79. doi:10.1016/S2468-1253(19)30186-4
   PubMed Web of Science ®Google Scholar
• Wheat CL, Ko CW, Clark-Snustad K, Grembowski D, Thornton TA, Devine B. Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis. BMC Gastroenterol. 2017;17(1):52. doi:10.1186/s12876-017-0602-0
   PubMedGoogle Scholar
• Danese S, Semeraro S, Papa A, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005;11(46):7227–7236. doi:10.3748/wjg.v11.i46.7227
   PubMed Web of Science ®Google Scholar
• Kaine J, Song X, Kim G, et al. Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using US administrative claims data. J Manag Care Spec Pharm. 2018;24:01–11.
   Google Scholar
• Boehncke W-H. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol. 2018;9:579. doi:10.3389/fimmu.2018.00579
   PubMed Web of Science ®Google Scholar
• Varani S, Landini MP. Cytomegalovirus-induced immunopathology and its clinical consequences. Herpesviridae. 2011;2(1):6. doi:10.1186/2042-4280-2-6
   PubMedGoogle Scholar
• Berry R, Watson GM, Jonjic S, et al. Modulation of innate and adaptive immunity by cytomegaloviruses. Nat Rev Immunol. 2020;20(2):113–127. doi:10.1038/s41577-019-0225-5
   PubMed Web of Science ®Google Scholar
• Powell RD, Warner NE, Levine RS, Kirsner JB. Cytomegalic inclusion disease and ulcerative colitis; report of a case in a young adult. Am J Med. 1961;30(2):334–340. doi:10.1016/0002-9343(61)90105-X
   PubMed Web of Science ®Google Scholar
• Tun GSZ, Raza M, Hale MF, et al. Polymerase chain reaction for detection of mucosal cytomegalovirus infection in patients with acute ulcerative colitis. Ann Gastroenterol. 2019;32(1):81–87. doi:10.20524/aog.2018.0318
   PubMed Web of Science ®Google Scholar
• Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1756–1767. doi:10.1053/j.gastro.2011.02.016
   PubMed Web of Science ®Google Scholar
• Roblin X, Pillet S, Oussalah A, et al. Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. Am J Gastroenterol. 2011;106(11):2001–2008. doi:10.1038/ajg.2011.202
   PubMed Web of Science ®Google Scholar
• Wethkamp N, Nordlohne EM, Meister V, et al. Identification of clinically relevant cytomegalovirus infections in patients with inflammatory bowel disease. Mod Pathol. 2018;31(3):527–538. doi:10.1038/modpathol.2017.149
   PubMed Web of Science ®Google Scholar
• Wada Y, Matsui T, Matake H, et al. Intractable ulcerative colitis caused by cytomegalovirus infection: a prospective study on prevalence, diagnosis, and treatment. Dis Colon Rectum. 2003;46(10 Suppl):S59–S65. doi:10.1097/01.DCR.0000087486.21981.C6
   PubMed Web of Science ®Google Scholar
• Yerushalmy-Feler A, Padlipsky J, Cohen S. Diagnosis and management of CMV colitis. Curr Infect Dis Rep. 2019;21(2):5. doi:10.1007/s11908-019-0664-y
   PubMed Web of Science ®Google Scholar
• Jones A, McCurdy JD, Loftus EV Jr, et al. Effects of antiviral therapy for patients with inflammatory bowel disease and a positive intestinal biopsy for cytomegalovirus. Clin Gastroenterol Hepatol. 2015;13(5):949–955. doi:10.1016/j.cgh.2014.09.042
   PubMed Web of Science ®Google Scholar
• Gauss A, Rosenstiel S, Schnitzler P, et al. Intestinal cytomegalovirus infection in patients hospitalized for exacerbation of inflammatory bowel disease: a 10-year tertiary referral center experience. Eur J Gastroenterol Hepatol. 2015;27(6):712–720. doi:10.1097/MEG.0000000000000361
   PubMed Web of Science ®Google Scholar
• McCurdy JD, Jones A, Enders FT, et al. A model for identifying cytomegalovirus in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015;13(1):131–e7. doi:10.1016/j.cgh.2014.05.026
   PubMed Web of Science ®Google Scholar
• Shukla T, Singh S, Tandon P, McCurdy JD. Corticosteroids and thiopurines, but not tumor necrosis factor antagonists, are associated with cytomegalovirus reactivation in inflammatory bowel disease: a systematic review and meta-analysis. J Clin Gastroenterol. 2017;51(5):394–401. doi:10.1097/MCG.0000000000000758
   PubMed Web of Science ®Google Scholar
• Su WP, Liu HN. Diagnostic criteria for sweet’s syndrome. Cutis. 1986;37(3):167–174.
   PubMed Web of Science ®Google Scholar
• Ayyash AM, Sampath R. Acute Febrile Neutrophilic Dermatosis. N Engl J Med. 2021;385(4):e14. doi:10.1056/NEJMicm2033219
   PubMed Web of Science ®Google Scholar
• Strickland I, Rhodes LE, Flanagan BF, Friedmann PS. TNF-alpha and IL-8 are upregulated in the epidermis of normal human skin after UVB exposure: correlation with neutrophil accumulation and E-selectin expression. J Invest Dermatol. 1997;108(5):763–768. doi:10.1111/1523-1747.ep12292156
   PubMed Web of Science ®Google Scholar
• Belhadjali H, Marguery MC, Lamant L, Giordano-Labadie F, Bazex J. Photosensitivity in sweet’s syndrome: two cases that were photoinduced and photoaggravated. Br J Dermatol. 2003;149(3):675–677. doi:10.1046/j.1365-2133.2003.05487.x
   PubMed Web of Science ®Google Scholar
• Sleiman J, Hitawala AA, Cohen B, et al. Systematic review: sweet syndrome associated with inflammatory bowel disease. J Crohns Colitis. 2021;15(11):1864–1876. doi:10.1093/ecco-jcc/jjab079
   PubMed Web of Science ®Google Scholar
• Esposito I, Fossati B, Peris K, De Simone C. A rare case of bullous sweet’s syndrome in a patient with inactive ulcerative colitis. J Eur Acad Dermatol Venereol. 2019;33(10):e380–e381. doi:10.1111/jdv.15674
   PubMed Web of Science ®Google Scholar
• Giannoni M, Rizzetto G, Sapigni C, et al. Bullous sweet’s syndrome in a patient with ulcerative colitis: a rare case report. Acta Dermatovenerol Alp Pannonica Adriat. 2020;29(3):153–155.
   PubMed Web of Science ®Google Scholar
• Miranda E, Meza R, Kolbach M, et al. Sweet syndrome in pediatric active ulcerative colitis. Am J Gastroenterol. 2021;116(2):234. doi:10.14309/ajg.0000000000000645
   PubMed Web of Science ®Google Scholar
• Saultz J, Garzon R. Acute myeloid leukemia: a concise review. J Clin Med. 2016;5(3):33. doi:10.3390/jcm5030033
   PubMed Web of Science ®Google Scholar
• Fabry TL, Sachar DB, Janowitz HD. Acute myelogenous leukemia in patients with ulcerative colitis. J Clin Gastroenterol. 1980;2(3):225–227. doi:10.1097/00004836-198009000-00003
   PubMed Web of Science ®Google Scholar
• Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut. 2005;54:617–622. doi:10.1136/gut.2004.051771
   PubMed Web of Science ®Google Scholar
• Cuttner J. Increased incidence of acute promyelocytic leukemia in patients with ulcerative colitis. Ann Intern Med. 1982;97:864–865. doi:10.7326/0003-4819-97-6-864
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Wong KK, Frank PH, et al. Acute leukemia following inflammatory bowel disease. Dig Dis Sci. 1982;27(6):545–548. doi:10.1007/BF01296735
   PubMed Web of Science ®Google Scholar
• Mir Madjlessi SH, Farmer RG, Weick JK. Inflammatory bowel disease and leukemia. A report of seven cases of leukemia in ulcerative colitis and Crohn’s disease and review of the literature. Dig Dis Sci. 1986;31(10):1025–1031. doi:10.1007/BF01300254
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Nakase K, Nagaya S, et al. Acute promyelocytic leukemia following ulcerative colitis. Rinsho Ketsueki. 1995;36(7):707–709.
   PubMedGoogle Scholar
• Lopez A, Mounier M, Bouvier AM, et al. Increased risk of acute myeloid leukemias and myelodysplastic syndrome in patients who received thiopurine treatment for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12(8):1324–1329. doi:10.1016/j.cgh.2014.02.026
   PubMed Web of Science ®Google Scholar
• Khan N, Patel D, Trivedi C, et al. Incidence of acute myeloid leukemia and myelodysplastic syndrome in patients with inflammatory bowel disease and the impact of thiopurines on their risk. Am J Gastroenterol. 2021;116(4):741–747. doi:10.14309/ajg.0000000000001058
   PubMed Web of Science ®Google Scholar
• Scoville SD, Nalin AP, Chen L, et al. Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood. 2018;132(17):1792–1804. doi:10.1182/blood-2018-03-838474
   PubMed Web of Science ®Google Scholar
• Yadav PK, Chen C, Liu Z. Potential role of NK cells in the pathogenesis of inflammatory bowel disease. J. Biomed Biotechnol. 2011;2011:348530.
   PubMedGoogle Scholar
• Murase T, Hotta T, Saito H, Ohno R. Effect of recombinant human tumour necrosis factor on the colony growth of human leukemia progenitor cells and normal haematopoietic progenitor cells. Blood. 1987;69:467–472. doi:10.1182/blood.V69.2.467.467
   PubMed Web of Science ®Google Scholar
• Nair B, Raval G, Mehta P. TNF-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of the literature. Am J Hematol. 2007;82(11):1022–1024. doi:10.1002/ajh.20926
   PubMed Web of Science ®Google Scholar
• Cesarini M, Vernia P, Angelucci E. Acute lymphoid leukemia in a Crohn’s disease patient during treatment with Adalimumab after a prolonged treatment with azathioprine and steroids. Inflamm Bowel Dis. 2010;16(3):371–372. doi:10.1002/ibd.21005
   PubMed Web of Science ®Google Scholar
• Li B, Zhu Z, Long S, et al. Acute myeloid leukemia with myelodysplasia-related changes in a patient with Crohn’s disease treated with immunosuppressive therapy. Case Rep Oncol. 2018;11(2):573–576. doi:10.1159/000491573
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhao K, Shen Q, et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature. 2015;525(7569):389–393. doi:10.1038/nature15252
   PubMed Web of Science ®Google Scholar
• Zhao LP, Boy M, Azoulay C, et al. Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease. Leukemia. 2021;35:2720–2724. doi:10.1038/s41375-021-01152-1
   PubMed Web of Science ®Google Scholar
• Cheng B, Rong A-M, Li W, et al. DNMT3a-mediated enterocyte barrier dysfunction contributes to ulcerative colitis via facilitating the interaction of enterocytes and B cells. Mediators Inflamm. 2022;2022:4862763. doi:10.1155/2022/4862763
   PubMed Web of Science ®Google Scholar
• Cumbo C, Tarantini F, Zagaria A, et al. Clonal hematopoiesis at the crossroads of inflammatory bowel diseases and hematological malignancies: a biological link? Front Oncol. 2022;12:873896. doi:10.3389/fonc.2022.873896
   PubMed Web of Science ®Google Scholar